Stockwatch: The Lexicon Of Biotech Survival
Silver Linings Like Positive Cardiovascular Outcome Studies Rarely Focus On The Clouds
Executive Summary
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.